Table 5.
Estimated haplotype frequencies of HLA class II loci
| DRB1-DQA1-DQB1 haplotype | % | |||||||
| Controls | PM | DM | Other antibodiesa | |||||
| Overall | Overall | AS | Mi-2 | PM-Scl | U1-RNP | SRP | ||
| 2n = 284 | 2n = 220 | 2n = 208 | 2n = 98 | 2n = 36 | 2n = 22 | 2n = 24 | 2n = 12 | |
| 04-03-03 | 20.4 | 16.4 | 19.1 | 17.3 | 13.8 | 4.5 | 37.5 | 0 |
| 03-05-02b | 16.5 | 33.6 | 24.5 | 43.9 | 8.3 | 54.5 | 12.5 | 4.1 |
| 02-01-06 | 13.7 | 9.1 | 9.6 | 10.2 | 8.3 | 4.5 | 20.8 | 25.0 |
| 01-01-05 | 10.6 | 11.8 | 13.5 | 7.1 | 22.2 | 9.1 | 16.7 | 8.3 |
| 13-01-06 | 10.2 | 6.4 | 5.8 | 6.1 | 0 | 4.5 | 1.0 | 8.3 |
| 07-02-02c | 9.2 | 4.1 | 13.9 | 7.1 | 33.3 | 18.2 | 0 | 0 |
| 11-05-03 | 4.6 | 7.3 | 5.3 | 2.0 | 5.6 | 0 | 0 | 16.7 |
| 07-02-03 | 3.9 | 0.4 | 3.8 | 0 | 5.6 | 0 | 1.0 | 0 |
Probabilities stated are corrected for multiple comparisons. Haplotypes found in less than 3% of controls are excluded from the table. aPolymyositis and dermatomyositis patients combined. bPM versus controls, p = 1.1 × 10-4, odds ratio (OR) 2.6 (95% confidence interval (CI) 1.6–4.0); AS versus controls, p = 7 × 10-10, OR 4.8 (CI 2.8–8.3); PM-Scl versus controls, p = 0.001, OR 6.1 (CI 2.2–16.5). cPM versus DM, p = 0.004, OR 0.3 (CI 0.1–0.6); Mi-2 versus controls, p = 0.002, OR 4.9 (CI 2.0–11.6). AS, anti-tRNA synthetase positive; DM, dermatomyositis; PM, polymyositis.